独立行政法人 医薬品医療機器総合機構
Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Summary of Investigation Results

Regorafenib hydrate

April 21, 2026

Non-proprietary name

Regorafenib hydrate

Brand name (marketing authorization holder)

Stivarga tablets 40mg (Bayer Yakuhin, Ltd.)

Japanese market launch

May 2013

Indications

○ Unresectable, advanced or recurrent colorectal cancer
○ Gastrointestinal stromal tumour that has progressed after cancer chemotherapy
○ Unresectable hepatocellular carcinoma that has progressed after cancer chemotherapy

Summary of revisions

“Hyperammonaemia” should be added to the 11.1 Clinically Significant Adverse Reactions section in 11. ADVERSE REACTIONS.

Investigation results and background of the revision

Cases involving hyperammonaemia were evaluated. Cases of hyperammonaemia not accompanied by abnormal hepatic function were identified, and those for which a causal relationship to regorafenib hydrate was reasonably possible have been reported. As a result of consultation with expert advisors regarding the causality assessment of the cases and the necessity of revision of PRECAUTIONS, the MHLW/PMDA concluded that revision of PRECAUTIONS was necessary.

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Reference: Number of cases* and patient mortalities involving hyperammonaemia reported in Japan and overseas

A total of 13 cases have been reported in Japan to date (including 7 cases in which a causal relationship between the drug and the event was reasonably possible).
No patient mortalities have been reported in Japan to date.

A total of 7 cases have been reported overseas to date (including 1 case in which a causal relationship between the drug and the event was reasonably possible).
No patient mortalities have been reported overseas to date.

*Cases collected in the PMDA's safety database for drugs

The expert advisors present at the Expert Discussion regarding the current investigation were nominated based on their conflict of interest declarations concerning the relevant products, pursuant to the “Rules for Convening Expert Discussions, etc., by the Pharmaceuticals and Medical Devices Agency” (PMDA Administrative Rule No. 20-8, dated December 25, 2008).